Pancreatic Cancer Research

ResearcherHarvard UniversityNo recent work listed

Harvey J. Mamon

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6060-9059; OpenAlex author ID A5083203430. Sources: ClinicalTrials.gov.

Their work

Papers
15 (first author 1, last author 2)
Trials
2 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
42
Papers, trials and grants by year

2001: 1 trial · 2002: none · 2003: none · 2004: none · 2005: none · 2006: none · 2007: none · 2008: none · 2009: 1 trial · 2010: none · 2011: 3 papers · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: none · 2016: none · 2017: 3 papers · 2018: 2 papers · 2019: none · 2020: none · 2021: 1 paper

Papers 15

  1. Development and validation of a pancreatic cancer risk model for the general population using electronic health records: An observational study. Co-author DOI 10.1016/j.ejca.2020.10.019↗
  2. Pilot study on the impact of F18-labeled thymidine PET/CT on gross tumor volume identification and definition for pancreatic cancer. Co-author DOI 10.1016/j.prro.2017.09.008↗
  3. Association Between Very Small Tumor Size and Decreased Overall Survival in Node-Positive Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6832-8↗
  4. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Co-author DOI 10.1093/annonc/mdx180↗
  5. Reply to the letter to the editor 'Borderline resectable pancreatic cancer: an evolving concept' by Petrucciani et al. Co-author DOI 10.1093/annonc/mdx273↗
  6. Assessment of the Utility of Laparoscopy and Peritoneal Cytology in the Staging of Pancreatic Cancer. Last author DOI 10.1097/mpa.0000000000000866↗
  7. A phase 1/2 and biomarker study of preoperative short course chemoradiation with proton beam therapy and capecitabine followed by early surgery for resectable … Co-author DOI 10.1016/j.ijrobp.2014.03.034↗
  8. Delaying chemoradiation until after completion of adjuvant chemotherapy for pancreatic cancer may not impact local control. Co-author DOI 10.1016/j.prro.2013.07.006↗
  9. Phase I study of neoadjuvant accelerated short course radiation therapy with photons and capecitabine for resectable pancreatic cancer. First author DOI 10.1016/j.radonc.2013.10.027↗
  10. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1634/theoncologist.2014-0086↗
  11. Chemoradiation therapy: localized esophageal, gastric, and pancreatic cancer. Co-author DOI 10.1016/j.soc.2013.02.005↗
  12. Prevalence and significance of subcentimeter hepatic lesions in patients with localized pancreatic adenocarcinoma. Last author DOI 10.1016/j.prro.2012.02.004↗
  13. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B… Co-author DOI 10.1002/cncr.25742↗
  14. Phase I study of preoperative short-course chemoradiation with proton beam therapy and capecitabine for resectable pancreatic ductal adenocarcinoma of the head. Co-author DOI 10.1016/j.ijrobp.2009.10.061↗
  15. Pancreatic cancer tumor size on CT scan versus pathologic specimen: implications for radiation treatment planning. Co-author DOI 10.1016/j.ijrobp.2010.04.058↗

Trials 2

  1. Neoadjuvant Accelerated Short Course Radiation Therapy With Photons and Capecitabine for Resectable Pancreatic Cancer Principal investigator NCT00889187↗
  2. Combination Chemotherapy and Radiation Therapy in Treating Patients With Pancreatic Cancer Study chair NCT00026130↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Theodore Sunki Hong · 10 shared papers, 2011–2018 · strength 0.49
  2. Jennifer Yon-Li Wo · 6 shared papers, 2013–2018 · strength 0.32
  3. Carlos F. Fernandez-del Castillo · 6 shared papers, 2011–2018 · strength 0.28
  4. Brian Matthew Wolpin · 4 shared papers, 2014–2017 · strength 0.22
  5. Atul Bhanudas Shinagare · 3 shared papers, 2012–2017 · strength 0.18
  6. Cristina Rosa Ferrone · 3 shared papers, 2014–2018 · strength 0.15
  7. Michael Hayden Rosenthal · 2 shared papers, 2017 · strength 0.15
  8. John W. Gilbert · 2 shared papers, 2017 · strength 0.15
  9. Thomas E. Clancy · 2 shared papers, 2017 · strength 0.15
  10. Jennifer L. Pretz · 2 shared papers, 2013–2018 · strength 0.14
  11. David P. Ryan · 4 shared papers, 2011–2014 · strength 0.13
  12. Lawrence Scott Blaszkowsky · 4 shared papers, 2011–2014 · strength 0.13
  13. Eunice Lee Kwak · 4 shared papers, 2011–2014 · strength 0.13
  14. Martin Rinard · 1 shared paper, 2021 · strength 0.11
  15. Sebastien Haneuse · 1 shared paper, 2021 · strength 0.11
  16. Limor Appelbaum · 1 shared paper, 2021 · strength 0.11
  17. Mari A. Mino-Kenudson · 2 shared papers, 2011–2017 · strength 0.10
  18. Vinayak Muralidhar · 1 shared paper, 2018 · strength 0.08
  19. Aparna R. Parikh · 1 shared paper, 2018 · strength 0.08
  20. Ryan David Nipp · 1 shared paper, 2018 · strength 0.08
  21. Stephen A. Mihalcik · 1 shared paper, 2017 · strength 0.07
  22. Charles S. Fuchs · 2 shared papers, 2011–2014 · strength 0.06
  23. Carlos Fernández-del Castillo · 1 shared paper, 2014 · strength 0.04
  24. Keith D. Lillemoe · 1 shared paper, 2014 · strength 0.04
  25. Shereef M. Elnahal · 1 shared paper, 2012 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.